



Chlorion Shareholders Elect Mr. Patrick Walsh to the Board of Directors

LAVAL, QC, January 20 -- Chlorion Pharma Inc. today announced that the company's shareholders have elected Mr. Patrick Walsh as an independent Director on the Board of Directors, effective immediately.

"We are all extremely pleased to have Pat join us," stated Dr. Jeffrey Coull, Chlorion's President and CEO. "He brings a wealth of relevant experience to the company, from both an operational and a strategic perspective".

Having spent decades as an entrepreneur and pharmaceutical executive, Mr. Walsh was most recently the CEO of Kadmus Pharmaceuticals, a California-based biopharmaceutical company developing endocannabinoid compounds for use in neuropathic pain and other conditions. Kadmus was recently acquired by Organon BioSciences. Prior to his work at Kadmus, Mr. Walsh was President and COO of Gensia Sidor, a publicly traded specialty pharmaceutical company.

Mr. Walsh joins Dr. Martial Lacroix, Ms. Isabelle Dusfresne, Mr. Jean-Francois Leprince and Dr. Jeffrey Coull on Chlorion's Board of Directors.

About the Company

Chlorion Pharma Inc. is a biopharmaceutical company focused on neurotherapeutics that act via the modulation of chloride in the central nervous system. Presently, the company is developing first-in-class therapeutics for the treatment of neuropathic pain and epilepsy.

For more information, please visit our website at www.chlorion.com.

##